Key result
The Cleveland Clinic rotodynamic blood pump demonstrated low hemolysis during initial in vivo testing and exceeded 12 months of continuous function in endurance bench testing.
The Cleveland Clinic rotodynamic blood pump shows promising initial in vitro and in vivo function, including low hemolysis and >12 months of bench endurance, supporting its development as a permanent ventricular assist device.
The Cleveland Clinic Foundation has developed a unique rotodynamic blood pump for future use as a permanent implant. This pump is small (2.5 x 2.5 inches) and requires an electric input power of 7 watts to produce 5 L/min of blood flow against 100 mm Hg at 3,000 rpm. Initial in vivo testing has confirmed in vitro function and shown low hemolysis. Endurance bench testing has exceeded 12 months of continuous function. This pump is the basis of an innovative ventricular assist system in which power is supplied by a tranocutaneous electrical transmission system, and pacer technology is used for both control logic and telemetry functions. The resulting system will be completed and tested under an NHLBI contract during the next 5 years.
No takes yet. Share an insight, caveat, or question.
Golding et al. (1996) studied this question. Cleveland Clinic rotodynamic blood pump was evaluated on In vitro function, hemolysis, and endurance bench testing. The Cleveland Clinic rotodynamic blood pump demonstrated low hemolysis during initial in vivo testing and exceeded 12 months of continuous function in endurance bench testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: